应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02268 药明合联
休市中 11-08 16:08:45
25.350
-0.350
-1.36%
最高
26.500
最低
24.950
成交量
4,386万
今开
26.000
昨收
25.700
日振幅
6.03%
总市值
303.97亿
流通市值
303.97亿
总股本
11.99亿
成交额
10.72亿
换手率
3.66%
流通股本
11.99亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
药明合联赢得2024 World ADC大奖,蝉联"最佳CDMO冠军"
美通社 · 11-08 11:50
药明合联赢得2024 World ADC大奖,蝉联"最佳CDMO冠军"
南向资金11月7日净卖出药明合联39.30万股 连续3日减持
市场透视 · 11-08 09:30
南向资金11月7日净卖出药明合联39.30万股 连续3日减持
【券商聚焦】国信证券维持药明合联(02268)“优于大市”评级 料公司未来3年业务将保持较快增长
金吾财讯 · 11-07
【券商聚焦】国信证券维持药明合联(02268)“优于大市”评级 料公司未来3年业务将保持较快增长
药明合联(02268)上涨5.14%,报25.55元/股
金融界 · 11-07
药明合联(02268)上涨5.14%,报25.55元/股
港股药明系走高,药明合联(02268.HK)涨7%,药明康德(02359.HK)涨近6%,药明生物(02269.HK)涨超3%。
美港电讯 · 11-06
港股药明系走高,药明合联(02268.HK)涨7%,药明康德(02359.HK)涨近6%,药明生物(02269.HK)涨超3%。
药明合联(02268)上涨5.36%,报24.55元/股
金融界 · 11-06
药明合联(02268)上涨5.36%,报24.55元/股
药明合联:抗体偶联药物CRDMO龙头企业 一体化平台赋能药物生产开发
国信证券 · 11-06
药明合联:抗体偶联药物CRDMO龙头企业 一体化平台赋能药物生产开发
南向资金10月25日净买入药明合联19.85万股 连续3日增持
市场透视 · 10-28
南向资金10月25日净买入药明合联19.85万股 连续3日增持
药明合联(02268)下跌5.37%,报22.9元/股
金融界 · 10-24
药明合联(02268)下跌5.37%,报22.9元/股
药明合联(02268)上涨5.56%,报24.7元/股
金融界 · 10-21
药明合联(02268)上涨5.56%,报24.7元/股
港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量
智通财经 · 10-18
港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量
药明合联10月17日主力资金流出598万元 连续3日减仓
市场透视 · 10-17
药明合联10月17日主力资金流出598万元 连续3日减仓
药明合联(02268)下跌5.03%,报20.75元/股
金融界 · 10-17
药明合联(02268)下跌5.03%,报20.75元/股
药明合联(02268)下跌5.17%,报22.95元/股
金融界 · 10-15
药明合联(02268)下跌5.17%,报22.95元/股
再迎政策利好!药品概念股集体活跃
财华社 · 10-10
再迎政策利好!药品概念股集体活跃
药明合联(02268)下跌5.07%,报23.4元/股
金融界 · 10-09
药明合联(02268)下跌5.07%,报23.4元/股
药明合联10月08日获主力加仓572万元 环比增加323.70%
市场透视 · 10-08
药明合联10月08日获主力加仓572万元 环比增加323.70%
医药板块普遍回调 泰格医药(03347)跌24.33% 机构指短期内板块或全面迎来报复式反弹
金吾财讯 · 10-08
医药板块普遍回调 泰格医药(03347)跌24.33% 机构指短期内板块或全面迎来报复式反弹
药明合联10月04日获主力加仓1022万元 环比增加302.36%
市场透视 · 10-04
药明合联10月04日获主力加仓1022万元 环比增加302.36%
药明合联(02268)股价上升5.364%,现价港币$27.5
阿斯达克财经 · 10-04
药明合联(02268)股价上升5.364%,现价港币$27.5
加载更多
公司概况
公司名称:
药明合联
所属市场:
SEHK
上市日期:
--
主营业务:
WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物(ADC)及更广泛生物偶联药物的合同研究、开发和生产服务(CRDMO)的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组,该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物,该公司还提供跨领域的综合服务,涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范(GMP)生产。该公司在国内外市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":25.35,"timestamp":1731053325030,"preClose":25.7,"halted":0,"volume":43860800,"delay":0,"floatShares":1199107777,"shares":1199107777,"eps":0.2992165,"marketStatus":"休市中","marketStatusCode":7,"change":-0.35,"latestTime":"11-08 16:08:45","open":26,"high":26.5,"low":24.95,"amount":1071550140,"amplitude":0.060311,"askPrice":25.4,"askSize":2500,"bidPrice":25.35,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.5311164873630773,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731288600000},"adr":0,"listingDate":1700150400000,"adjPreClose":25.7,"openAndCloseTimeList":[[1731029400000,1731038400000],[1731042000000,1731052800000]],"volumeRatio":8.908638560846281,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2481902031","title":"药明合联赢得2024 World ADC大奖,蝉联\"最佳CDMO冠军\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902031","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481902031?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:50","pubTimestamp":1731037800,"startTime":"0","endTime":"0","summary":"中国上海和美国圣地亚哥2024年11月8日 /美通社/ -- 全球领先的专注于提供抗体偶联药物等生物偶联药物端到端CRDMO服务的药明合联,近日在2024 World ADC奖评选中荣膺\"最佳 CDMO冠军\",这是公司连续第二年荣获该项殊荣。此外,公司已连续三年在World ADC奖中斩获多项荣誉,包括2022年\"最佳CMO亚军\"以及2023年\"最佳CDMO冠军\"。本届World ADC大会上,药明合联还获得了\"最佳CRO\"和\"最佳ADC平台技术\"的提名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4551571_ZH51571_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","CDMO","BK4139","SG9999014674.SGD","BK4080","BK1141","02268","BK4231"],"gpt_icon":0},{"id":"2481169974","title":"南向资金11月7日净卖出药明合联39.30万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2481169974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481169974?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:30","pubTimestamp":1731029416,"startTime":"0","endTime":"0","summary":"11月7日,南向资金减持药明合联39.30万股连续3日减持。截止当日收盘,港股通共持有药明合联10145.01万股,占流通股8.44%。药明合联近5个交易日上涨11.26%,港股通累计减持26.40万股;近20个交易日上涨13.97%,港股通累计增持987.81万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093215a22221b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093215a22221b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2481910931","title":"【券商聚焦】国信证券维持药明合联(02268)“优于大市”评级 料公司未来3年业务将保持较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2481910931","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481910931?lang=zh_cn&edition=full","pubTime":"2024-11-07 13:12","pubTimestamp":1730956359,"startTime":"0","endTime":"0","summary":"2021-2023年公司三年营收复合增速180.4%、归母净利润复合增速120.9%。该行指,根据药明合联招股说明书,预计2030年ADC市场规模将增长至647亿美元。综合能力领先,多重优势打造六大核心竞争力:1)多项顶级技术加该行表示,维持“优于大市”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NDM0MmU4OTRhMjU2ZjIzMGMyNTgwMjU0NDY3MDU0NTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NDM0MmU4OTRhMjU2ZjIzMGMyNTgwMjU0NDY3MDU0NTg=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","002736"],"gpt_icon":0},{"id":"2481130119","title":"药明合联(02268)上涨5.14%,报25.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481130119","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481130119?lang=zh_cn&edition=full","pubTime":"2024-11-07 11:02","pubTimestamp":1730948572,"startTime":"0","endTime":"0","summary":"11月7日,药明合联(02268)盘中上涨5.14%,截至11:02,报25.55元/股,成交5512.39万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/07110245024594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2481692390","title":"港股药明系走高,药明合联(02268.HK)涨7%,药明康德(02359.HK)涨近6%,药明生物(02269.HK)涨超3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2481692390","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481692390?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:41","pubTimestamp":1730860907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0856984785.SGD","BK1576","LU0326950275.SGD","LU0572944931.SGD","SG9999002463.SGD","IE00B0JY6N72.USD","LU0052750758.USD","BK1589","02359","LU2125910500.SGD","BK1521","BK1141","LU0979878070.USD","LU1688375341.USD","603259","LU0043850808.USD","LU0456842615.SGD","LU0456827905.SGD","LU0823426308.USD","LU1242518931.SGD","LU0516422366.SGD","HSTECH","LU0516422440.USD","LU0320764599.SGD","LU0588546209.SGD","YANG","LU2045819591.USD","LU0051755006.USD","LU0516423091.SGD","LU1997245177.USD","LU1242518857.USD","LU2488822045.USD","LU0823426480.USD","LU2039709279.SGD","LU0348735423.USD","LU0181495838.USD","LU0348825331.USD","LU0327786744.USD","LU0039217434.USD","LU0516422952.EUR","02269","BK1610","LU1997245094.SGD","HSCEI","LU0359201612.USD","LU0359202008.SGD","LU2242644610.SGD","02268","LU0417516738.SGD","07226"],"gpt_icon":0},{"id":"2481911126","title":"药明合联(02268)上涨5.36%,报24.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481911126","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481911126?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:16","pubTimestamp":1730859409,"startTime":"0","endTime":"0","summary":"11月6日,药明合联(02268)盘中上涨5.36%,截至10:16,报24.55元/股,成交4959.22万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/06101644978472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2481610772","title":"药明合联:抗体偶联药物CRDMO龙头企业 一体化平台赋能药物生产开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2481610772","media":"国信证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481610772?lang=zh_cn&edition=full","pubTime":"2024-11-06 00:00","pubTimestamp":1730822400,"startTime":"0","endTime":"0","summary":"公司为全球抗体偶联药物CRDMO 龙头企业。药明合联为全球领先的抗体偶联药物合同研究、开发及生产组织,为客户提供全流程端到端服务,赋能药物生产开发全过程,综合能力领先。根据药明合联招股说明书,预计2030年ADC 市场规模将增长至647 亿美元。由于生物偶联药物开发的高难度性,ADC 外包率居高不下,预计到2030 年,全球ADC 及更广泛生物偶联药物的外包服务市场规模将扩张至110 亿美元,ADC 外包服务公司大有可为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110613261895bdd7ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110613261895bdd7ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2478603117","title":"南向资金10月25日净买入药明合联19.85万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2478603117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478603117?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:30","pubTimestamp":1730079017,"startTime":"0","endTime":"0","summary":"10月25日, 南向资金增持药明合联19.85万股,连续3日增持。截止当日收盘,港股通共持有药明合联9907.16万股,占流通股8.25%。药明合联近5个交易日下跌0.43%,港股通累计增持166.30万股;近20个交易日上涨18.64%,港股通累计增持1769.22万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028093234ab7991d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028093234ab7991d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","02268","BK1141"],"gpt_icon":0},{"id":"2477526042","title":"药明合联(02268)下跌5.37%,报22.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477526042","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477526042?lang=zh_cn&edition=full","pubTime":"2024-10-24 13:21","pubTimestamp":1729747318,"startTime":"0","endTime":"0","summary":"10月24日,药明合联(02268)盘中下跌5.37%,截至13:21,报22.9元/股,成交3765.65万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/24132144379385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2477022896","title":"药明合联(02268)上涨5.56%,报24.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477022896","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477022896?lang=zh_cn&edition=full","pubTime":"2024-10-21 10:23","pubTimestamp":1729477380,"startTime":"0","endTime":"0","summary":"10月21日,药明合联(02268)盘中上涨5.56%,截至10:23,报24.7元/股,成交2975.07万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/21102344225721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2476411142","title":"港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2476411142","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476411142?lang=zh_cn&edition=full","pubTime":"2024-10-18 10:57","pubTimestamp":1729220234,"startTime":"0","endTime":"0","summary":"光大证券认为,今年以来,针对创新药领域,多项利好政策陆续出台。随着政策落地,创新药发展有望迈入快车道。国投证券指出,国谈进入常态化阶段,创新药长期放量可期。2024年医保谈判预计将于近期开启,多个国产创新药将参加本年度医保谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02256","BK1161","BK1588","06978","BK1515","159992","02105","SG9999014674.SGD","LU2488822045.USD","09939","09969","159938","BK1574","02268","09688"],"gpt_icon":0},{"id":"2476304194","title":"药明合联10月17日主力资金流出598万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2476304194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476304194?lang=zh_cn&edition=full","pubTime":"2024-10-17 16:15","pubTimestamp":1729152920,"startTime":"0","endTime":"0","summary":"10月17日, 药明合联股价跌4.35%,报收20.90元,成交金额9451万元,换手率0.37%,振幅8.24%,量比0.62。药明合联今日主力资金净流出598万元,连续3日净流出,上一交易日主力净流出645万元,今日环比减少7.29%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为50.00%,平均跌幅为2.54%。该股近5个交易日下跌8.20%,主力资金累计净流入156万元;近20日主力资金累计净流入4684万元,其中净流入天数为11日。该股主力净额占比0.02%,港股市场排名2439/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101716153395aefdc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101716153395aefdc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2476196536","title":"药明合联(02268)下跌5.03%,报20.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2476196536","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476196536?lang=zh_cn&edition=full","pubTime":"2024-10-17 15:43","pubTimestamp":1729151032,"startTime":"0","endTime":"0","summary":"10月17日,药明合联(02268)盘中下跌5.03%,截至15:43,报20.75元/股,成交8697.6万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/17154344101711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2475143535","title":"药明合联(02268)下跌5.17%,报22.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2475143535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475143535?lang=zh_cn&edition=full","pubTime":"2024-10-15 14:49","pubTimestamp":1728974960,"startTime":"0","endTime":"0","summary":"10月15日,药明合联(02268)盘中下跌5.17%,截至14:49,报22.95元/股,成交6943.66万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/15144944006177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","02268","SG9999014674.SGD"],"gpt_icon":0},{"id":"2474763073","title":"再迎政策利好!药品概念股集体活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2474763073","media":"财华社","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474763073?lang=zh_cn&edition=full","pubTime":"2024-10-10 14:02","pubTimestamp":1728540175,"startTime":"0","endTime":"0","summary":"10月10日,港A两市的药品板块走势活跃。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202410_1/13b6e829-c490-4a22-9f8f-05d7e24f0c85.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202410_1/13b6e829-c490-4a22-9f8f-05d7e24f0c85.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67076e0f53243c06e31e71a2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["HK0000306685.HKD","LU0067412154.USD","SG9999014674.SGD","LU1008478684.HKD","IE00BZ08YR35.GBP","SG9999004220.SGD","IE00B031HY20.USD","BK1589","LU0326950275.SGD","LU1226287792.SGD","LU0140636845.USD","LU1226287875.USD","BK1161","IE00B5MMRT66.SGD","09969","HK0000320264.USD","09995","LU1960683339.HKD","BK1587","BK1576","HK0000320223.HKD","BK1521","LU1226287529.USD","BK1583","LU0501845795.SGD","01548","LU0072913022.USD","06978","01093","IE00BZ08YT58.USD","LU1951186391.HKD","LU1152091168.USD","LU1993786604.SGD","LU0880133367.SGD","IE00BZ08YS42.EUR","00013","01801","03692","BK1574","BK1191","BK1588","IE0008368742.USD","LU1969619763.USD","LU2328871848.SGD","IE00B543WZ88.USD","LU1152091754.HKD","IE0008369823.USD","LU1807302812.USD","LU1226288253.USD","02268"],"gpt_icon":1},{"id":"2474537292","title":"药明合联(02268)下跌5.07%,报23.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474537292","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474537292?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:58","pubTimestamp":1728439097,"startTime":"0","endTime":"0","summary":"10月9日,药明合联(02268)盘中下跌5.07%,截至09:58,报23.4元/股,成交1.02亿元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO),具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告,该公司是全球第二大ADC等生物偶联药物CRDMO,市场份额从2020年的1.8%增长至2022年的9.8%,显示出迅速的业务拓展和市场占有率的提升。截至2024年中报,药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/09095843815114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2473412130","title":"药明合联10月08日获主力加仓572万元 环比增加323.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473412130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473412130?lang=zh_cn&edition=full","pubTime":"2024-10-08 16:16","pubTimestamp":1728375369,"startTime":"0","endTime":"0","summary":"10月08日, 药明合联股价跌12.43%,报收24.65元,成交金额3.41亿元,换手率1.13%,振幅17.41%,量比1.23。药明合联今日主力资金净流入572万元,连续5日净流入,上一交易日主力净流入135万元,今日环比增加323.70%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为80.00%,平均涨幅为2.44%。该股近5个交易日上涨6.64%,主力资金累计净流入3236万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入6778万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410081617439f31764d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410081617439f31764d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2473418264","title":"医药板块普遍回调 泰格医药(03347)跌24.33% 机构指短期内板块或全面迎来报复式反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2473418264","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473418264?lang=zh_cn&edition=full","pubTime":"2024-10-08 14:45","pubTimestamp":1728369901,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药板块普遍回调,泰格医药 跌24.33%,方达控股跌23.36%,复旦张江跌22.32%,药明康德跌13.19%,药明生物跌12.56%,药明合联跌11.55%。中航证券研报指出,医药板块经历长时间回调,已经处于估值、政策、情绪触底阶段,伴随本次宽货币政策密集出台,短期内板块或全面迎来报复式反弹,“创新”及“估值修复”或成为主要关键词。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1945515","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","03347","BK0028","BK1515","LU0516422440.USD","BK1576","LU2125910500.SGD","LU1794554557.SGD","01349","BK1610","LU1242518931.SGD","LU1720050803.USD","BK1521","BK1583","LU0348825331.USD","SG9999014674.SGD","LU0051755006.USD","LU0052750758.USD","IE00B0JY6N72.USD","01521","LU0327786744.USD","LU0039217434.USD","LU0456846285.SGD","LU1820825898.SGD","BK1191","LU2045819591.USD","02359","LU0979878070.USD","09939","LU1688375341.USD","LU2242644610.SGD","LU0307460666.USD","02268","BK1574","LU1146622755.USD","02269","SG9999002463.SGD","LU1242518857.USD","LU0417516738.SGD","SG9999002562.SGD","LU0140636845.USD","BK0174","300347","BK1589","LU1046422090.SGD","LU0516422366.SGD","159938","LU0043850808.USD","LU0588546209.SGD"],"gpt_icon":1},{"id":"2472593851","title":"药明合联10月04日获主力加仓1022万元 环比增加302.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472593851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472593851?lang=zh_cn&edition=full","pubTime":"2024-10-04 16:15","pubTimestamp":1728029720,"startTime":"0","endTime":"0","summary":"10月04日, 药明合联股价涨3.45%,报收27.00元,成交金额2.16亿元,换手率0.67%,振幅6.70%,量比0.60。药明合联今日主力资金净流入1022万元,连续3日净流入,上一交易日主力净流入254万元,今日环比增加302.36%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为53.85%,平均涨幅为2.94%。该股近5个交易日上涨32.03%,主力资金累计净流入6334万元;近20日主力资金累计净流入6795万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410041615329f28a8b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410041615329f28a8b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2472782988","title":"药明合联(02268)股价上升5.364%,现价港币$27.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2472782988","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472782988?lang=zh_cn&edition=full","pubTime":"2024-10-04 13:14","pubTimestamp":1728018840,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午01:14比前收市价上升5.364%,现股价为港币$27.5。至目前为止,今日最高价为$27.5,而最低价为$25.95。总成交量为476.961万股,总成交金额为港币$1.275亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2410044935/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.1217},{"period":"1month","weight":0.1242},{"period":"3month","weight":0.3556},{"period":"6month","weight":0.33},{"period":"1year","weight":0.2306},{"period":"ytd","weight":-0.2078}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0044},{"period":"3month","weight":0.2129},{"period":"6month","weight":0.093},{"period":"1year","weight":0.1837},{"period":"ytd","weight":0.2159}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物(ADC)及更广泛生物偶联药物的合同研究、开发和生产服务(CRDMO)的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组,该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物,该公司还提供跨领域的综合服务,涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范(GMP)生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}